New Horizons for Host Defense Peptides and Lantibiotics

Overview

Journal Curr Opin Pharmacol

Specialty Pharmacology

Date 2012 Jul 11

PMID 22776251

Citations 20

Authors

Michael John Dawson

Richard W Scott

Affiliations

Soon will be listed here.

Abstract

Antimicrobial peptides from either microbial sources, or based on host defense peptides (HDPs) from higher organisms, show promising activity against human pathogens. Lantibiotics have been extensively engineered by either molecular biology approaches or chemistry and both natural and modified entities have been shown to have good efficacy in animal models of infection. Amongst HDPs either truncated peptides or non-peptide mimetic molecules show substantial promise both for their direct antibiotic action and also modulation of host functions. Members of both classes have reached clinical development for therapy of systemic infections and Clostridium difficile infection of the gastrointestinal tract.

Citing Articles

Nanomedicine for drug resistant pathogens and COVID-19 using mushroom nanocomposite inspired with bacteriocin - A review.

Srinivash M, Krishnamoorthi R, Mahalingam P, Malaikozhundan B, Bharathakumar S, Gurushankar K Inorg Chem Commun. 2023; 152:110682.

PMID: 37041990 PMC: 10067464. DOI: 10.1016/j.inoche.2023.110682.

Lactic Acid Bacteria (LAB): Autochthonous and Probiotic Microbes for Meat Preservation and Fortification.

Lahiri D, Nag M, Sarkar T, Ray R, Shariati M, Rebezov M Foods. 2022; 11(18).

PMID: 36140920 PMC: 9498044. DOI: 10.3390/foods11182792.

Semisynthetic Macrocyclic Lipo-lanthipeptides Display Antimicrobial Activity Against Bacterial Pathogens.

Zhao X, Xu Y, Viel J, Kuipers O ACS Synth Biol. 2021; 10(8):1980-1991.

PMID: 34347446 PMC: 8383303. DOI: 10.1021/acssynbio.1c00161.

Biotechnological Insights on the Expression and Production of Antimicrobial Peptides in Plants.

Shanmugaraj B, Bulaon C, Malla A, Phoolcharoen W Molecules. 2021; 26(13).

PMID: 34279372 PMC: 8272150. DOI: 10.3390/molecules26134032.

Nisin- and Ripcin-Derived Hybrid Lanthipeptides Display Selective Antimicrobial Activity against .

Zhao X, Kuipers O ACS Synth Biol. 2021; 10(7):1703-1714.

PMID: 34156232 PMC: 8291769. DOI: 10.1021/acssynbio.1c00080.

References

Jabes D, Brunati C, Candiani G, Riva S, Romano G, Donadio S . Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens. Antimicrob Agents Chemother. 2011; 55(4):1671-6. PMC: 3067139. DOI: 10.1128/AAC.01288-10. View

Claudon P, Violette A, Lamour K, Decossas M, Fournel S, Heurtault B . Consequences of isostructural main-chain modifications for the design of antimicrobial foldamers: helical mimics of host-defense peptides based on a heterogeneous amide/urea backbone. Angew Chem Int Ed Engl. 2009; 49(2):333-6. DOI: 10.1002/anie.200905591. View

Yang L, Gordon V, Mishra A, Som A, Purdy K, Davis M . Synthetic antimicrobial oligomers induce a composition-dependent topological transition in membranes. J Am Chem Soc. 2007; 129(40):12141-7. DOI: 10.1021/ja072310o. View

Scott M, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, Thompson A . An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol. 2007; 25(4):465-72. DOI: 10.1038/nbt1288. View

Lai Y, Gallo R . AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009; 30(3):131-41. PMC: 2765035. DOI: 10.1016/j.it.2008.12.003. View

Braunstein A, Papo N, Shai Y . In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob Agents Chemother. 2004; 48(8):3127-9. PMC: 478488. DOI: 10.1128/AAC.48.8.3127-3129.2004. View

Dijkshoorn L, Brouwer C, Bogaards S, Nemec A, van den Broek P, Nibbering P . The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004; 48(12):4919-21. PMC: 529198. DOI: 10.1128/AAC.48.12.4919-4921.2004. View

Mookherjee N, Lippert D, Hamill P, Falsafi R, Nijnik A, Kindrachuk J . Intracellular receptor for human host defense peptide LL-37 in monocytes. J Immunol. 2009; 183(4):2688-96. DOI: 10.4049/jimmunol.0802586. View

Ghobrial O, Derendorf H, Hillman J . Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrob Agents. 2008; 33(1):70-4. PMC: 2643042. DOI: 10.1016/j.ijantimicag.2008.07.028. View

10.

van der Does A, Bogaards S, Ravensbergen B, Beekhuizen H, van Dissel J, Nibbering P . Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrob Agents Chemother. 2009; 54(2):811-6. PMC: 2812139. DOI: 10.1128/AAC.00652-09. View

11.

Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K . Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol. 2006; 127(3):594-604. DOI: 10.1038/sj.jid.5700599. View

12.

Richards S, Strandberg K, Gunn J . Salmonella-regulated lipopolysaccharide modifications. Subcell Biochem. 2010; 53:101-22. DOI: 10.1007/978-90-481-9078-2_5. View

13.

Goldstein B, Wei J, Greenberg K, NOVICK R . Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model. J Antimicrob Chemother. 1998; 42(2):277-8. View

14.

BAVIN E, BEACH A, Falconer R, FRIEDMANN R . Nisin in experimental tuberculosis. Lancet. 1952; 1(6699):127-9. DOI: 10.1016/s0140-6736(52)92429-x. View

15.

Yang D, Biragyn A, Kwak L, Oppenheim J . Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 2002; 23(6):291-6. DOI: 10.1016/s1471-4906(02)02246-9. View

16.

Lupetti A, Brouwer C, Bogaards S, Welling M, de Heer E, Campa M . Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. J Infect Dis. 2007; 196(9):1416-24. DOI: 10.1086/522427. View

17.

Gersemann M, Wehkamp J, Stange E . Innate immune dysfunction in inflammatory bowel disease. J Intern Med. 2012; 271(5):421-8. DOI: 10.1111/j.1365-2796.2012.02515.x. View

18.

Mota-Meira M, Morency H, Lavoie M . In vivo activity of mutacin B-Ny266. J Antimicrob Chemother. 2005; 56(5):869-71. DOI: 10.1093/jac/dki295. View

19.

Ghobrial O, Derendorf H, Hillman J . Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci. 2009; 99(5):2521-8. DOI: 10.1002/jps.22015. View

20.

Li M, Cha D, Lai Y, Villaruz A, Sturdevant D, Otto M . The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol Microbiol. 2007; 66(5):1136-47. DOI: 10.1111/j.1365-2958.2007.05986.x. View